Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The user-provided name “VRMA mRNA” appears to be a misspelling or variant of VIRMA mRNA, referring to the messenger RNA transcribed from the human VIRMA (Vir like m6A methyltransferase associated) gene. VIRMA encodes a protein component of the RNA N6-methyladenosine (m6A) methyltransferase complex (often termed the m6A “writer” complex), where it acts as an associated/regulatory subunit rather than the catalytic core. It enables RNA binding activity, is involved in mRNA processing, and is localized to the m6A methyltransferase complex, cytosol, and nuclear speckles. Functionally, VIRMA is a key regulator of m6A methylation of mRNAs in the 3′-UTR near the stop codon, recruiting the catalytic subunits METTL3 and METTL14 and thereby guiding site-specific m6A deposition. This activity influences mRNA splicing, RNA processing, and mRNA polyadenylation/alternative polyadenylation. Dysregulation or variation of VIRMA has been associated with hepatocellular carcinoma and Wilms tumor, indicating a role in oncogenesis, although VIRMA mRNA itself is not currently a direct, established drug target like a receptor, ion channel, or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VIRMA mRNA (VIRMA).